Breast magnetic resonance imaging (MRI) is indisputably the highest sensitivity test available to detect breast cancer, revealing more extensive cancer in the ipsilateral and otherwise occult cancer in the contralateral breasts when used before surgery. The use of preoperative breast MRI has become somewhat controversial, because the clinical benefit of the heightened detection provided by MRI has been questioned in the context of multidisciplinary breast cancer treatment, relatively low local recurrence, and metachronous contralateral cancer rates. Also, MRI detection rates have been compared with the high rates reported in the pathology literature. The emerging clinical outcome literature is showing conflicting results to demonstrating actual overall benefit. Critical review of this literature reveals several misconceptions about MRI detection rates and limitations of many of the published outcome studies to date, which render the results not necessarily generalizable to contemporary optimized breast MRI practices. This article addresses some of the misconceptions raised by critics, provides a critical review of the clinical outcome literature, reviews patient subgroups anticipated to have the highest yield when using preoperative MRI, makes recommendations for optimizing breast MRI practice, and suggests areas for potential future research.
Breast magnetic resonance imaging (MRI) has been used on the global scale for more than 20 years; its use has more dramatically increased over the last 10 years. It is indisputably the highest sensitivity test available to detect breast cancer, revealing more extensive cancer in the ipsilateral and otherwise occult cancer in the contralateral breasts compared with any method currently available when used before surgery in women with breast cancer. In a meta-analysis of 19 studies evaluating breast MRI in the preoperative setting, MRI detected otherwise occult cancer in the ipsilateral breast in 11.1% of cases [1] . In a meta-analysis of 22 studies evaluating detection in the contralateral breast at the time of diagnosis, MRI found an additional 4.1% of cancers compared with mammography with or without the use of ultrasound, similar to findings in a large multicentre prospective trial of an added 3.1% cancer detection rate [2, 3] . In the preoperative setting, the anticipated clinical benefits that arise from this heightened detection are as follows:
1. improved surgical planning that results in decreased reoperation rates and better stratification of patients suited to breast conserving surgery (BCS) vs mastectomy 2. decrease in breast recurrence rates by resecting otherwise occult multifocal and/or multicentric tumour 3. decreased metachronous contralateral cancer rates by simultaneous detection and treatment at the time of index cancer treatment.
In the context of multidisciplinary breast cancer treatment and relatively low rates of local recurrence, estimated at 5%e11%, the added value of MRI has come into question [4, 5] . As the clinical outcome literature begins emerging, the use of breast MRI for preoperative staging is proving not to be a straightforward issue. The aims of this article are to review theoretically posed arguments against preoperative breast MRI, outcome literature that addressed the proposed benefits and claims of potential harms caused, requirements for an optimized breast MRI practice, recommendations for use, and directions for future investigation.
Theoretical Arguments Against Clinical Benefit
Pathology studies of whole breast specimens have established that additional cancer foci are often present in the breast diagnosed with cancer, at much greater rates than that diagnosed before surgery by using Mx and clinical breast examination (CBE). It is argued that the higher cancer detection rate by using breast MRI is also much greater than breast recurrence rates after BCS and modern adjuvant therapies, and this leads to surgical overtreatment of biologically irrelevant cancer foci that would otherwise be treated with adjuvant therapies.
However, although the extent of disease detected by MRI in the ipsilateral breast closer approximates the levels reported in pathology studies compared with standard imaging and CBE, it does not reach these high levels. Furthermore, the MRI detection rate is closer to recurrence rates than detection rates based on pathologic assessment. A meta-analysis of studies that investigated preoperative breast MRI in patients with a diagnosed index cancer reported MRI detected additional ipsilateral disease, including false-positive examinations, in 16% (range, 6%e34%) of patients. The cancer detection rate of additional histologically proven multifocal or multicentric cancer reported was 11.3% [1] . Pathology studies have reported the presence of Mx and clinically occult additional cancer foci in 21%e63% of cases [6e9] . By using mastectomy specimen pathology as a reference standard, Sardanelli et al [10] reported that MRI had a lower false negative rate for detecting all cancer foci in patients with a diagnosed breast cancer, compared with Mx (19% [36/188] vs 34% [64/188]). Also, the cancer foci missed by breast MRI were smaller (mean size, 5 mm), with a more favorable ratio of invasive-tononinvasive foci, compared with Mx, (mean size, 5 mm vs 8 mm; 1:1 vs 2.5:1) [10] .
The clinical benefit of contralateral breast cancer detection has also been questioned. It is argued that the increased contralateral cancer detection rate when using MRI is greater than the metachronous cancer rate at follow-up. Because invasive ipsilateral cancers are usually treated with systemic therapies, eradication of existing but undetected contralateral cancer is anticipated. Support of this theory comes from data published by the Early Breast Cancer Trialists' Collaborative Group in an overview of the randomized clinical trials. They found that, at a 15-year follow-up, the contralateral cancer rate was reduced by 50% after 5 years of tamoxifen and by 20% in patients who received adjuvant chemotherapy [11, 12] .
In a meta-analysis of the studies that evaluated MRI added detection of contralateral cancer, the MRI contralateral detection rate at the time of cancer diagnosis was 4% [2] . The 10-year cumulative incident rates of metachronous contralateral cancers are reported at less than 5%, and 5-year rates at 3% [13e15]. The synchronous cancer detection rate of 4% is similar to the 5-year rate of 3% and arguably can decrease this more relevant shorter follow-up metachronous rate. In a meta-analysis of the data, Brennan et al [2] found the false-negative rate of breast MRI in the contralateral breast for the subset of patients undergoing prophylactic mastectomy to be 12%. Similar to the findings in the ipsilateral breast when using mastectomy specimen as the criterion standard, MRI does not detect all cancer foci, arguably missing those most likely to remain subclinical.
The concept that MRI is not simply identifying all cancer present akin to pathology studies but rather can serve as an in vivo biomarker of tumour biological significance has been raised. Jansen et al [16] published their results on the physiologic basis of ductal carcinoma in situ (DCIS) enhancement when using a murine model. Because the gadolinium was found within the lumens of neoplastic ducts, they postulated that the gadolinium reached the lumen by diffusing out of the capillaries into the extravascular space, through leaky basement membranes of the ducts, damaged by proteases secreted by the neoplastic cells. They further hypothesized that the resulting leakiness of the basement membrane may prove an important biomarker of a lesion's likelihood of becoming invasive [16] . In the follow-up commentary, Kuhl [17] further postulates that DCIS detected on high-quality MRI provides more prognostically relevant information than that detected on Mx, which is based on calcifications caused by regressive tumour changes.
Results of Clinical Outcome Studies

Margins: Reoperation Rates
The comparative effectiveness of MRI in breast cancer (COMICE) trial is the first randomized control trial (RCT) to evaluate reoperation rates for breast cancer in groups of women that did and did not undergo preoperative breast MRI. The trial was performed between 2001 and 2007 and enrolled more than 1600 patients in 45 centres. It was designed to determine if patients undergoing preoperative breast MRI experience better surgical outcomes measured by number of repeated operations for positive margins. Turnbull et al [18] reported no change in reoperation rates, which occurred in 19% of both groups undergoing breast MRI in addition to standard triple assessment (CBE, imaging with Mx and US, depending on the institution recruiting and percutaneous needle sampling) compared with those randomized to no MRI and concluded there was no benefit to adding preoperative breast MRI.
A similar failure to decrease reoperation rates for patients diagnosed with invasive breast cancer ultimately excised to negative margins on BCS was published by Hwang et al [19] from University Health Network in Toronto on retrospective review of 472 initially planned lumpectomies between 1999 and 2005. The investigators found similar reoperation rates for the MRI group (11.3%) compared with the group not undergoing MRI (13.3%) (P ¼ .5) [19] .
Because RCTs are considered the most rigorous criterion standard of study designs, being a RCT, COMICE is seemingly an ideal study to answer the question: ''Does preoperative breast MRI reduce reoperation rates?'' Although the RCT design eliminates some means of bias against MRI, inherent in observational retrospective studies as will be discussed later; COMICE introduced different forms of bias against MRI. To recruit the number of patients required in a reasonable time frame, the number of centres that participated was high (45 centres), which likely introduced a broad spectrum of breast MRI experience and recruitment capabilities. Based on the internal quality-assurance assessment, 8% of the examinations were technically noncompliant in the study, most from low-recruitment centres [18] . Addressing the importance of experience required for breast MRI interpretation in a single institution study, Warner et al [20] reported that the ability to detect DCIS by MRI in a highrisk screening study, significantly improved with radiologist experience. Because the COMICE trial found a lower contralateral cancer detection rate of 1.6%, compared with the American College of Radiology Imaging Network (ACRIN) 6667 multicentre trial rate of 3.1% and the 4.1% reported by Brennan et al [2] in a meta-analysis of pooled data, this may indicate inferior technical and interpretive factors compared with contemporary best practice [3, 18] .
To interpret the results of these studies, we must understand the study limitations that render them nongeneralizable. Because the end point in the Toronto study was reoperation rates to a point of breast conservation only, excluding patients requiring repeated operation to mastectomy, a significant number of relevant patients in the equation of improving reoperation rates were likely excluded. Also, the potential benefits MRI may provide, such as how often MRI altered surgical management, are not reported based on inclusion criteria. Because this was a retrospective study, there is an inherent bias against the MRI group, because patients who typically undergo MRI clinically typically have a higher likelihood for more extensive Mx occult disease because of the high risk and high breast density.
In the Toronto study and the many centres in the COMICE trial, preoperative US staging was used rigorously before MRI staging, which limited their results in the context of the MRI practice in the same centres. During the time frame the studies were conducted, there was very limited if any MRI-guided biopsy, relying on post-MRI directed US for biopsy guidance. The anticipated yield of additional cancer detection on a second-look US is very low in the context of an initial US negative examination. As a result, little expected benefit is to be derived from breast MRI in practices that also use US staging but without MRI-guided biopsy. Consequently, the results can apply only to practices with preoperative breast MRI in the context as they were used in these studies.
Furthermore, reference to multidisciplinary discussions on altered plans of management based on MRI findings was not made in either study. Given the complex multitude of images to review and interpret, the translation of the MRI-based information to the surgeon is equally as critical as the interpretation. The potential success of preoperative breast MRI hinges on this relayed information and could also account for the lack of decreasing reoperation rates in both studies.
Outcome data that supported breast MRI come from Mann et al [21] in their retrospective study performed in 2 highly experienced MRI centres. They included all consecutive patients diagnosed with invasive lobular carcinoma and compared reoperation and final mastectomy rates between 2 groups: patients who did and did not receive preoperative breast MRI. The investigators reported that the re-excision rates were reduced in patients who underwent breast MRI (9%) compared with those who did not (27%) (P ¼ .010) and found that there was a trend towards a decreased mastectomy rate (48%) in the group that underwent MRI compared with the group that did not (59%) (P ¼.098) [21] . Importantly, how this study differs from the COMICE trial and the Toronto study is the fact that patients were discussed and treatment plans were devised by a multidisciplinary team of breast cancer specialists. Also, the centres are highly experienced at MRI-guided biopsy, and MRI findings required pathology proof before altering management, either by MRI-directed US if the lesion was visible, or by biopsy using MRI guidance [22] .
Finally, assessing reoperation rates as an end point in isolation is complicated, because surgical oncology practices evolve with time, and the goals themselves are not standardized. For instance, the quality-assurance standard for the UK National Health Service Breast Screening Programme set a goal of reducing the reoperation rate for positive margins to under 10%, which can be achieved by very wide excisions at the expense of cosmesis [18] . In her Lancet commentary, Morris [23] addressed the problem created by the lack of standardized goals across centres. Higher reoperation rates, approximating 25%, are acceptable in her centre as the surgeons attempt to optimize cosmesis by limiting normal tissue excision.
Mastectomy Rates Increased
The argument that breast MRI can lead to surgical overtreatment of biologically irrelevant cancer, in the context of adjuvant radiation and systemic therapies, is made by studies that link increasing mastectomy rates to use of breast MRI.
In a retrospective review of the experience at the Mayo Clinic, Katipamula et al [24] reported on the trends of mastectomy rates relative to periods before and after use of preoperative breast MRI. They found that, after an initial decline in overall rates from 45% in 1997 to 31% in 2003, the rates then increased to as high as 45% by 2006. During the time frame 2003-2006, the use of MRI more than doubled, from 10% to 23%. Although patients who underwent MRI were more likely to undergo mastectomy (54% vs 36%, P < .0001), the rate within this group remained relatively stable. However, the mastectomy rate significantly increased in the group that did not receive MRI (29%e41%, P < .001) over the same time frame [24] . Inherent in this retrospective study design, again, is a selection bias, concentrating the patients who are more likely at the highest risk for more extensive disease into the MRI group and, therefore, are more likely to undergo mastectomy. Interestingly, they found the highest increase in mastectomy rates in patients not undergoing breast MRI, which underscored the multifactorial reasons behind patients who chose mastectomy. Irrespective of the extent of cancer, patient factors found to be associated with increased likelihood of mastectomy include higher education level, younger age, and those offered immediate reconstruction [25, 26] .
False Positives: Increased Surgery Based on False Positives
Preoperative breast MRI has been criticized for causing pathologically unnecessary more-extensive surgery than initially planned based on false-positive findings. In a metaanalysis of preoperative breast MRI studies, Houssami et al [1] found that more extensive surgery was performed based on false-positive MRI findings (ie, MRI detected suspicious but not biopsy confirmed lesions), including conversion from lumpectomy to wider excision in 4.4% and from lumpectomy to mastectomy in 1.1% of cases [1] . In the COMICE trial, 38% of patients whose surgery was converted to mastectomy based on MRI findings were because of false-positive findings [18] . This is important and is hoped to be historical information, which emphasizes the need for changes in surgical management to be based on biopsy proof of more extensive disease and not only on imaging findings. Because many of these studies were performed before any or ready availability of MRIguided biopsy, the results are acceptable to practice standards within the study time frames. However, in contemporary practice, breast MRI with MRI-guided biopsy available should not account for such pathologically unnecessary surgery, because this practice is no longer justifiable.
Recurrence Rates
Data that evaluated proposed relationships between use of breast MRI and local recurrence rates have recently emerged. In a retrospective review that assessed recurrence rates after breast conserving treatment for early stage breast cancer in patients treated between 1992e2001, Solin et al [27] reported no change in local recurrence rates at an 8-year follow-up, including a 3% rate for those patients who underwent breast MRI compared with 4% in those patients who did not (P ¼ .51) [27] . However, only half of the MRI examinations were actually performed before surgery, the remaining half were after lumpectomy or after repeated reexcision, which is most often performed for positive margins. Not only does this enrich the MRI group to those more likely to recur based on margin status but introduces a greater diagnostic challenge for image interpretation unique to the postoperative setting compared with preoperative imaging.
Similarly, no difference in local recurrence rates was reported by Hwang et al [19] in a retrospective review of patients diagnosed with invasive breast cancer ultimately excised to negative margins on BCS, over a short follow-up time, median 54 months (range, 4.8e111.6 months). They found similar actuarial 8-year recurrence rates, 1.8% for the group undergoing MRI compared with 2.5% for those who did not (P ¼ .67) [19] . Whereas all breast MRI examinations included in this study were performed before surgery, in contrast to the study by Solin, both studies had many similar limitations, which must be understood to interpret the results and recognize their nongeneralizable nature [18, 27] . The benefit of MRI is likely to be underestimated in both studies, based on the inclusion criteria; excluding patients who required mastectomy for MRI detected extensive disease. Breast MRI was in its early stages during the time frame of both studies, and many advances have been made both technologically and interpretively. The recognition of more subtle appearances of cancer, including non-mass lesions, were beginning to be published in the last year (2001) of the Solin study [28, 29] . During the study time frames, the group at the University of Pennsylvania had much experience with MRI-guided wire localization and surgical biopsy, but MRI-guided percutaneous biopsy was just beginning, and little if any MRI-guided intervention was performed in the Toronto study [19, 27] . Based on the retrospective design of both studies, patients at higher risk are more likely to be recommended for MRI and, therefore, included in the MRI arm.
One study that demonstrated a positive impact of MRI on recurrence rates comes from Fischer et al [30] in a retrospective review of patients diagnosed with breast cancer from 1993e1997. They found a significantly lower recurrence rate of 1.2% in those patients who underwent preoperative breast MRI compared with 6.8% for those patients who did not (P < .001), at a minimum of a 20-month followup (mean, 40.3 months). Use of MRI-guided wire localization and surgical biopsy was used as outlined during the time of this study to verify MRI-only visible suspicious lesions. This study recorded final breast surgical outcome, including a higher mastectomy rate, of 39% compared with 29% for those patients who did not undergo breast MRI. Despite the retrospective nature and early time frame of this study, a decrease in recurrence rates was demonstrated. This study has been criticized, however, for potential biases against the no-MRI arm because of a lack of adjustments for age, tumour characteristics, and adjuvant systemic therapies. The relatively high local recurrence rate for the non-MRI group compared with contemporary practices at such a short follow-up interval is another criticism against its generalizability. Despite providing end surgical outcome rates of mastectomy or BCS for the 2 groups, the rates of altering surgical planning based on MRI findings was not provided.
Metachronous Contralateral Breast Cancer Rates
There is little clinical outcome data on breast MRI's ability to decrease the metachronous contralateral breast cancer rate. Detection of synchronous contralateral cancer is anticipated to affect rates at a relatively shorter follow-up period (about 1e5 years). The data available come from studies whose primary aims were evaluating ipsilateral breast recurrence rates between groups of patients who did and did not receive pre-or perioperative MRI. Fischer et al [30] published the only study that addressed the timing of contralateral cancer presentation and found a decreased rate of metachronous cancers in the MRI group compared with the no-MRI group (1.7% vs 4%, P < .001). The follow-up period was 14e52 months (mean, 35 month) [30] .
Solin et al [27] found no difference in the contralateral breast cancer rates at 8 years, 6% in both groups, but does not provide details about the timing of detection to determine if MRI affects metachronous rates. The average follow-up period in this study was 4.6 years but ranged from as low as 0.1 year to 13.5 years. However, during a shorter followup period, of 5 years, relevant to address this question, the detection rate in the MRI group was only 3% compared with 6% in the non-MRI group, which suggests that MRI may have had some effect in lowering metachronous contralateral cancer rates in this patient population [27] .
Optimizing Breast MRI Practice
It is apparent across all of the studies that evaluated preoperative breast MRI that the clinical outcome results can only be as good as the manner in which breast MRI is practiced. The results of studies that evaluated MRI during its early period or more recent studies, including practices in which breast MRI practice was not optimized and lack of MRI-guided biopsy capability are not generalizable to contemporary best breast MRI practice. The American College of Radiology (ACR) has published practice guidelines and technical standards that outline the basic minimum equipment and protocol requirements [31] . The ACR is launching its accreditation program for breast MRI, similar to that established for Mx and breast US, in attempt to ensure quality control and quality assurance for participating centres. Importantly, in the United States, accreditation will be required for reimbursement by Medicare for breast MRI examinations. One of the criteria required for accreditation will be MRI-guided biopsy capability or establishing a referral arrangement for MRI-guided biopsy with a cooperating facility.
Recommendations for Use
Recommended guidelines for using preoperative breast MRI have been published, developed to encompass those groups for whom MRI is anticipated to provide the highest diagnostic yield, based on limitations of mammographic sensitivity and highest pretest risk for the presence of multifocal and/or multicentric and contralateral cancer [1, 32] . Groups for whom preoperative breast MRI has been recommended based on highest anticipated yield are as follows:
1. mammographically dense breasts 2. known multifocal/multicentric disease or bilateral cancer 3. invasive lobular cancer 4. high risk for hereditary breast cancer 5. partial breast irradiation candidate However, any individual patient with a recent diagnosis of breast cancer can potentially benefit from preoperative breast MRI through the detection of otherwise occult cancer foci in the ipsilateral and contralateral breasts. Whereas Mx sensitivity worsens with greater breast density, breast density alone is not a perfect indicator of who will benefit from breast MRI. Lehman et al [3] found no difference in detection rates of Mx occult cancer in the contralateral breast when using MRI, based on breast density, with equal detection rates of 3% for fatty and dense breasts. In the context of screening women at high risk, Bigenwald et al [33] found, by using the Breast Imaging Reporting and Data System (BI-RADS) density classification, that whereas Mx sensitivity was slightly higher for low-density breasts (<50% density) compared with highdensity breasts (>50% density), it was poor when compared with MRI. The reported Mx sensitivity for low-density breasts was 33%, compared with 94% for MRI and 18% for high breast density compared with 86% for MRI [33] .
Lehman et al [3] also found other factors, including histology of the index cancer and menopausal status, were not predictors of diagnostic yield for detecting contralateral breast cancer with MRI. However, in the context of limited MRI resources available, individual practices may or may not choose to adopt guidelines based on highest anticipated yield of cancer detection.
Conclusions and Future Directions
On critical review of the preoperative breast MRI clinical outcome literature, it is apparent that the results are not generalizable but can be applied to programs that practice breast MRI in a manner similar to those in the published studies. The results do highlight the need for quality control and assurance in a breast MRI program to include MRIguided biopsy capability and a multidisciplinary approach to manage patients by incorporating the MRI results.
Within the context of an optimized breast MRI practice, continued investigation on how to best translate the extent of cancer information to the surgeon in the operating room could potentially decrease reoperation rates while optimizing cosmesis. Some strategies being explored include supine breast MRI and preoperative mapping techniques that involve prone MRI-guided wire localization and combined US and MRI mapping with the patient in the supine position [34, 35] .
Because there is no outcome data that stratify patient subgroups based on demonstrated benefit from preoperative breast MRI, future investigation is warranted. Data that link tumour biomarkers to outcomes such as recurrence risk and death from breast cancer are available and should be considered in future studies that look at benefits of preoperative MRI [36e39]. The MRI identification of tumours that could otherwise be untreated in the context of emerging targeted therapies in medical and radiation oncology is an area for potential investigation. One such therapeutic approach is the use of breast tumour multigene assays to personalize patient treatment according to risk for relapse by identifying patients likely to benefit or not from adjuvant chemotherapy. Another targeted therapy is the use of accelerated partial-breast irradiation (APBI) as an alternative to whole-breast irradiation, a technique that treats a limited volume of tissue around the lumpectomy site, significantly decreasing the dose to ''uninvolved'' breast and surrounding organs. Studies that evaluated preoperative breast MRI in candidates for APBI found that 6%-10% of patients had additional cancer foci detected by MRI that would not have been resected at initially planned lumpectomy planned on Mx, with or without US and CBE, nor treated with APBI [40, 41] .
Whereas breast MRI has been criticized for leading to surgical overtreatment, it is well recognized that, despite the known morbidities associated with radiation, many patients are likely overtreated with radiation when using conventional criteria for candidacy. By taking advantage of the high negative predictive value of MRI, it is conceivable that breast radiation can be avoided for certain subtypes of cancer if no additional disease is confirmed on high-quality MRI, an area that potentially warrants investigation.
Lastly, the preoperative breast MRI clinical outcome literature to date is conflicting to demonstrating benefit or not. It is apparent that more studies are necessary, ideally that involve breast MRI practices in more contemporary time periods, performing MRI at an ACR accreditation level, in a multidisciplinary setting. Ideally, future studies will be radiologist led or at least have significant input into study design from experienced radiologists familiar with the many variables that affect breast MRI.
